$1.89
2.33%
Nasdaq, Apr 21, 08:50 pm CET
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

NRX Pharmaceuticals Inc Stock price

$1.93
-0.12 5.85% 1M
+0.67 52.57% 6M
-0.27 12.27% YTD
-2.25 53.83% 1Y
-19.57 91.02% 3Y
-104.87 98.19% 5Y
-94.07 97.99% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.00 0.00%
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

Key metrics

Market capitalization $32.65m
Enterprise Value $37.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-19.70m
Free Cash Flow (TTM) Free Cash Flow $-10.64m
Cash position $1.44m
EPS (TTM) EPS $-2.41
P/E forward negative
P/S forward 0.56
EV/Sales forward 0.65
Short interest 8.66%
Show more

Is NRX Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

NRX Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a NRX Pharmaceuticals Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a NRX Pharmaceuticals Inc forecast:

Buy
100%

Financial data from NRX Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
0% 0%
-
-0.01 -0.01
0% 0%
-
- Selling and Administrative Expenses 14 14
5% 5%
-
- Research and Development Expense 6.20 6.20
54% 54%
-
-20 -20
29% 29%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -20 -20
29% 29%
-
Net Profit -25 -25
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about NRX Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NRX Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
about 7 hours ago
WILMINGTON, Del. , April 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that it will participate in an H.C.
Neutral
PRNewsWire
18 days ago
Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI , April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq:NRXP), today announced signing of a term sheet with a global medical devic...
Neutral
PRNewsWire
21 days ago
Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Stephen Durand, founder of Dura, to serve as Director of Clinic Oper...
More NRX Pharmaceuticals Inc News

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Head office United States
CEO Jonathan Javitt
Founded 2017
Website www.nrxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today